Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Trodelvy (sacituzumab govitecan) for the Treatment of Advanced Triple-Negative Breast Cancer

Drug Name

Trodelvy™ (sacituzumab govitecan-hziy)

Developer

Immunomedics

Therapy Class

Antibody-drug conjugate (ADC)

Product Description

Trop-2-directed antibody and topoisomerase inhibitor conjugate

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top